NASDAQ$XXII
22nd Century Group Inc. · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
22nd Century Group filed its 2019 annual report and maintained a strong balance sheet, with momentum continuing for its Modified Risk Tobacco Product and a major milestone achieved in hemp/cannabis research.
22nd Century Group filed its Annual Report on Form 10-K for the year ended December 31, 2019. The company is optimistic about the potential authorization of its Modified Risk Tobacco Product application and is making progress in the legal hemp/cannabis space through a partnership with KeyGene.
- Entered into Warrant Exercise Agreements generating gross proceeds of approximately $11.3 million.
- Conducted an initial closing of an investment in Panacea Life Sciences, Inc.
- FDA authorized the Company to sell its very low nicotine content tobacco cigarettes under the brand names Moonlight® and Moonlight Menthol®.
- Completed the first, high-density, hemp/cannabis genome sequencing through its partnership with KeyGene.
Headline financials
Revenue & EPS history
22nd Century Group · Revenue · Quarterly
$7.3M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2019
-2.9%
Avg return
Earnings day
-3.9%
Avg return
5 days after
-7.7%
Avg return
30 days after
32%
19 / 59 earnings
Positive
+37.4%
Q4 2020
Best reaction
-25.8%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -2.2% | -13.2% | — | |
| Q1 2026 | -16.6% | -33.2% | -44.0% | |
| Q3 2025 | -17.0% | -20.0% | -32.3% | |
| Q1 2025 | +1.9% | -18.7% | -59.3% | |
| Q4 2024 | -2.6% | -12.6% | -59.2% | |
| Q3 2024 | -3.0% | -10.7% | -28.2% | |
| Q2 2024 | -14.9% | -21.9% | -62.8% | |
| Q1 2024 | -1.9% | -9.7% | -47.9% | |
| Q4 2023 | -8.7% | -7.7% | -18.1% | |
| Q3 2023 | -15.2% | -19.0% | -52.5% | |
| Q2 2023 | -25.8% | -23.3% | -51.6% | |
| Q1 2023 | -5.0% | -13.8% | -16.1% | |
| Q4 2022 | -0.7% | -4.9% | -17.9% | |
| Q3 2022 | -21.0% | -13.8% | -26.1% | |
| Q2 2022 | -10.7% | -11.2% | -32.7% | |
| Q1 2022 | -8.3% | -20.3% | -3.1% | |
| Q4 2021 | -2.1% | -9.8% | -0.9% | |
| Q3 2021 | -0.7% | +1.7% | -22.1% | |
| Q2 2021 | +18.1% | +26.4% | +12.4% | |
| Q1 2021 | +8.4% | +10.7% | +14.9% | |
| Q4 2020 | +37.4% | +27.0% | +62.6% | |
| Q3 2020 | +13.2% | +12.5% | +129.0% | |
| Q2 2020 | -2.1% | -4.6% | -19.3% | |
| Q1 2020 | -3.6% | -9.9% | -7.7% | |
| Q4 2019 | -5.8% | +2.2% | -7.7% | |
| Q3 2019 | -3.6% | -10.2% | -40.8% | |
| Q2 2019 | +3.1% | +18.9% | +31.4% | |
| Q1 2019 | -11.4% | -18.6% | -18.1% | |
| Q4 2018 | +1.6% | +7.0% | +1.1% | |
| Q3 2018 | +3.1% | +0.8% | +9.8% | |
| Q2 2018 | -1.6% | +2.8% | +2.4% | |
| Q1 2018 | +6.8% | +23.2% | +7.7% | |
| Q4 2017 | +11.3% | +5.8% | -10.1% | |
| Q3 2017 | +0.0% | +5.8% | +28.6% | |
| Q2 2017 | -7.9% | -10.5% | +4.6% | |
| Q1 2017 | +6.9% | +6.9% | +40.5% | |
| Q4 2016 | +0.5% | +3.7% | +44.4% | |
| Q3 2016 | +0.8% | -0.8% | -21.2% | |
| Q2 2016 | +2.2% | +10.9% | +17.4% | |
| Q1 2016 | +2.6% | — | — | |
| Q4 2015 | -4.8% | — | — | |
| Q3 2015 | -9.3% | — | — | |
| Q2 2015 | -7.0% | — | — | |
| Q1 2015 | +21.5% | — | — | |
| Q4 2014 | -16.5% | — | — | |
| Q4 2013 | -16.5% | — | — | |
| Q3 2014 | -9.2% | — | — | |
| Q2 2014 | -1.4% | — | — | |
| Q1 2014 | -2.9% | — | — | |
| Q3 2013 | +4.2% | — | — | |
| Q2 2013 | -18.5% | — | — | |
| Q1 2013 | +0.0% | — | — | |
| Q4 2012 | -9.1% | — | — | |
| Q3 2012 | -20.0% | — | — | |
| Q2 2012 | -7.1% | — | — | |
| Q1 2012 | +1.5% | — | — | |
| Q4 2011 | +1.5% | — | — | |
| Q3 2011 | +0.0% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro